Alliancebernstein L.P. Purchases 84,255 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Alliancebernstein L.P. raised its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 3.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,286,994 shares of the company's stock after acquiring an additional 84,255 shares during the quarter. Alliancebernstein L.P. owned about 2.89% of Viridian Therapeutics worth $43,842,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Viridian Therapeutics by 4.0% in the fourth quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company's stock valued at $88,087,000 after purchasing an additional 174,952 shares during the last quarter. Geode Capital Management LLC grew its holdings in Viridian Therapeutics by 5.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,493,311 shares of the company's stock valued at $33,979,000 after buying an additional 81,951 shares in the last quarter. Loomis Sayles & Co. L P bought a new position in Viridian Therapeutics during the 4th quarter worth $26,845,000. Pictet Asset Management Holding SA lifted its holdings in shares of Viridian Therapeutics by 21.8% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,248,721 shares of the company's stock worth $23,938,000 after buying an additional 223,384 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Viridian Therapeutics by 11.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 575,070 shares of the company's stock valued at $11,024,000 after acquiring an additional 58,857 shares during the period.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research firms recently commented on VRDN. Needham & Company LLC reiterated a "buy" rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $27.00 target price (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Royal Bank of Canada boosted their price target on Viridian Therapeutics from $44.00 to $47.00 and gave the company an "outperform" rating in a research note on Tuesday, December 17th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a report on Monday, December 16th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $35.70.

Viridian Therapeutics Price Performance

Shares of VRDN stock traded down $0.21 on Monday, hitting $11.78. 1,153,319 shares of the company's stock were exchanged, compared to its average volume of 1,182,288. The company has a 50 day moving average of $16.18 and a 200 day moving average of $19.40. The stock has a market cap of $959.89 million, a P/E ratio of -2.73 and a beta of 0.81. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. Viridian Therapeutics, Inc. has a 12 month low of $10.93 and a 12 month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping analysts' consensus estimates of ($1.05) by $0.24. The firm had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. On average, equities research analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.